<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Nevoid basal cell carcinoma syndrome (Gorlin syndrome)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Nevoid basal cell carcinoma syndrome (Gorlin syndrome)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Nevoid basal cell carcinoma syndrome (Gorlin syndrome)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Benjamin Barankin, MD, FRCPC
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph MC Lam, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Stern, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            June K Robinson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 18, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nevoid basal cell carcinoma syndrome (NBCCS; MIM #109400) is a rare autosomal dominant, tumor-predisposing disorder caused by germline pathogenic variants in the human homolog of the patched (
         <em>
          PTCH1
         </em>
         ) gene [
         <a href="#rid1">
          1
         </a>
         ]. First described in 1894, the clinical manifestations of NBCCS were more clearly defined in 1960 by Gorlin and Goltz [
         <a href="#rid2">
          2
         </a>
         ]. Affected patients have multiple developmental anomalies, multiple basal cell carcinomas and odontogenic keratocysts of the jaw at an early age, and an increased risk of developing a medulloblastoma in early childhood [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Synonyms for NBCCS include Gorlin or Gorlin-Goltz syndrome; basal cell nevus syndrome (BCNS); multiple basal cell nevi, odontogenic keratocysts, and skeletal anomalies; bifid-rib basal-cell nevus syndrome; basal cell cancer syndrome; and multiple basal cell nevi.
        </p>
        <p>
         The pathogenesis, clinical manifestations, and management of NBCCS are reviewed here. Basal cell carcinoma is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5335.html" rel="external">
          "Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5338.html" rel="external">
          "Treatment and prognosis of basal cell carcinoma at low risk of recurrence"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13724.html" rel="external">
          "Treatment of basal cell carcinomas at high risk for recurrence"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3718529691">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nevoid basal cell carcinoma syndrome (NBCCS) is a rare disease. The prevalence is estimated between approximately 1 in 31,000 and 1 in 164,000 persons [
         <a href="#rid4">
          4-7
         </a>
         ]. However, the true prevalence may be higher as individuals with mild clinical manifestations may be not recognized.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nevoid basal cell carcinoma syndrome (NBCCS) is inherited as an autosomal dominant trait with a high degree of penetrance (approximately 97 percent) but variable expression [
         <a href="#rid8">
          8
         </a>
         ]. Most cases of NBCCS are caused by a pathogenic variant of
         <em>
          PTCH1
         </em>
         and, infrequently, by variants in the suppressor of fused (
         <em>
          SUFU
         </em>
         ) gene and
         <em>
          PTCH2
         </em>
         [
         <a href="#rid9">
          9-11
         </a>
         ]. However, in some cases, no pathogenic variant is identified. In an analysis of 182 patients with NBCCS, 69 percent had
         <em>
          PTCH1
         </em>
         variants, 5 percent had
         <em>
          SUFU
         </em>
         variants, and 26 percent had no pathogenic variant identified [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H74644248">
         <span class="h2">
          PTCH1 gene variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most cases, NBCCS is caused by germline inactivating variants involving
         <em>
          PTCH1
         </em>
         on chromosome 9q22.3 [
         <a href="#rid13">
          13-17
         </a>
         ]. Loss-of-function variants in
         <em>
          PTCH1
         </em>
         result in premature termination of the PTCH protein [
         <a href="#rid18">
          18-21
         </a>
         ]. (See
         <a class="local">
          'PTCH protein function'
         </a>
         below.)
        </p>
        <p>
         Loss of heterozygosity at this site in both hereditary and sporadic basal cell carcinomas (BCCs) suggests that it functions as a tumor suppressor gene [
         <a href="#rid22">
          22
         </a>
         ]. Acquired
         <em>
          PTCH1
         </em>
         variants have been found in approximately one-third of sporadic BCCs [
         <a href="#rid23">
          23,24
         </a>
         ], in a high proportion of xeroderma pigmentosum-associated BCCs, and in some sporadic medulloblastomas [
         <a href="#rid25">
          25,26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5335.html" rel="external">
          "Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma"
         </a>
         .)
        </p>
        <p>
         A two-hit model in
         <em>
          PTCH1
         </em>
         , similar to that described for the
         <em>
          RB1
         </em>
         gene in retinoblastoma, has been proposed to explain the pathogenesis of BCC, medulloblastoma, and other tumors in NBCCS [
         <a href="#rid27">
          27
         </a>
         ]. According to this model, in individuals who carry a germline defect in the deoxyribonucleic acid (DNA) sequence in one of the two copies of a tumor suppressor gene, a second (somatic) DNA injury at the same locus or loss of heterozygosity (loss of the normal remaining allele) is necessary for the cell to undergo malignant transformation and clonal expansion [
         <a href="#rid28">
          28,29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6275.html" rel="external">
          "Retinoblastoma: Clinical presentation, evaluation, and diagnosis", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1646384702">
         <span class="h2">
          PTCH protein function
         </span>
         <span class="headingEndMark">
          —
         </span>
         The PTCH protein is a receptor for the hedgehog (HH) protein, a component of the sonic hedgehog (SHH) signaling pathway  (
         <a class="graphic graphic_figure graphicRef76029" href="/z/d/graphic/76029.html" rel="external">
          figure 1
         </a>
         ). This pathway is important in determining tissue patterning and cell fate in multiple structures within the developing embryo [
         <a href="#rid30">
          30,31
         </a>
         ]. SHH signaling is activated when HH binds to its receptor, a complex that is formed by PTCH and a second protein, Smoothened (SMO), a transmembrane protein  (
         <a class="graphic graphic_figure graphicRef69105" href="/z/d/graphic/69105.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid32">
          32-36
         </a>
         ]. PTCH functions as a regulatory molecule for
         <em>
          SMO
         </em>
         , with PTCH-induced repression of
         <em>
          SMO
         </em>
         limiting the effect of the SHH signal [
         <a href="#rid33">
          33,36
         </a>
         ].
        </p>
        <p>
         According to this model, SMO repression is relieved following mutational inactivation of
         <em>
          PTCH1
         </em>
         in patients with NBCCS [
         <a href="#rid37">
          37
         </a>
         ]. This results in constitutive overexpression of the SHH signal, which has been implicated in the development of BCC and other tumors, possibly via activation of the transcription factors Gli1 and/or Gli2  (
         <a class="graphic graphic_figure graphicRef76029" href="/z/d/graphic/76029.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid31">
          31,33,38-42
         </a>
         ].
        </p>
        <p>
         Evidence supporting a link between overexpression of the SHH pathway and tumorigenesis is provided by studies in animal models and in vitro studies using tumor tissues from patients with NBCCS:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transgenic mice overexpressing SMO or SHH in the skin spontaneously produce skin lesions resembling human BCCs [
         <a href="#rid37">
          37,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Owing to failure of negative feedback, the mutant PTCH1 transcript is overexpressed in affected tissues. Such transcripts are found at high levels in BCCs and odontogenic keratocysts from patients with NBCCS but not in skin or other types of tumors [
         <a href="#rid44">
          44-46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H74644261">
         <span class="h2">
          SUFU gene variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Germline heterozygous loss-of-function variants in the
         <em>
          SUFU
         </em>
         gene on chromosome 10q24.32, encoding a component of the SHH/patched signaling pathway, have been found in individuals from families meeting the diagnostic criteria for Gorlin syndrome without variants in
         <em>
          PTCH1
         </em>
         [
         <a href="#rid3">
          3
         </a>
         ].
         <em>
          SUFU
         </em>
         mutations appear to be associated with milder clinical features (lower number of BCCs and no odontogenic keratocysts) but with a greatly increased risk of developing a childhood medulloblastoma [
         <a href="#rid12">
          12,47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H2372416098">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         More than 100 clinical abnormalities have been reported in nevoid basal cell carcinoma syndrome (NBCCS). The major manifestations are [
         <a href="#rid48">
          48
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early development of multiple basal cell carcinomas (BCCs)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Jaw odontogenic (bone) keratocysts
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Palmar and plantar pits  (
         <a class="graphic graphic_picture graphicRef72687" href="/z/d/graphic/72687.html" rel="external">
          picture 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lamellar calcification of the falx cerebri
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history (first-degree relative with NBCCS)
        </p>
        <p>
        </p>
        <p>
         Minor features include [
         <a href="#rid6">
          6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Craniofacial anomalies (macrocephaly, frontal bossing, hypertelorism)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vertebral/rib anomalies, such as bifid/splayed/extra ribs or bifid vertebrae
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cleft lip/palate
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polydactyly
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Childhood medulloblastomas
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac or ovarian fibromas, often bilateral
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphomesenteric or pleural cysts
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ocular anomalies (coloboma, cataract, glaucoma)
        </p>
        <p>
        </p>
        <p>
         Although medulloblastomas that are characteristically of the desmoplastic subtype tend to develop at a young age, many of the classic features of NBCCS (ie, BCCs, palmar pits, calcified falx cerebri) may not be detected until the late teens or young adulthood [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma"
         </a>
         .)
        </p>
        <p>
         The frequency of the major clinical findings may vary across different populations or ethnic groups. As an example, early-onset BCCs, jaw keratocysts, and a positive family history are detected in 71, 70, and 86 percent, respectively, of patients from populations of North European origin. In contrast, these same features are detected in 31, 90, and 43 percent, respectively, of those from East Asian populations [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2838497133">
         <span class="h2">
          Major features
         </span>
        </p>
        <p class="headingAnchor" id="H2874105488">
         <span class="h3">
          Basal cell carcinomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         BCCs are found in approximately three-fourths of non-Hispanic White patients with NBCCS but are less frequent in affected African American and East Asian patients [
         <a href="#rid49">
          49,50
         </a>
         ]. Age at first diagnosis ranges from 2 to 53 years old with an average age of 20 to 21 years. Common single nucleotide genetic polymorphisms in melanocortin-1 receptor gene (
         <em>
          MC1R
         </em>
         ) and
         <em>
          TERT
         </em>
         -
         <em>
          CLPTM1L
         </em>
         may be associated with an earlier age of onset of BCC in these patients [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         The number of BCCs can vary from only a few to thousands, and they range in size from 1 to 10 mm [
         <a href="#rid52">
          52,53
         </a>
         ]. BCCs frequently occur on sun-exposed areas, such as the head, neck, back, chest, and upper limbs, but they can occur in any location [
         <a href="#rid5">
          5,54
         </a>
         ]. BCCs arising in NBCCS are histologically indistinguishable from sporadic BCCs. The term "nevoid" does not refer to an association of the BCC with nevi but instead was coined because early lesions may be pigmented and have the appearance of nevi with a prominent vascular component. In some patients, the large tumor burden and the need for multiple surgical procedures result in significant disfigurement and poor quality of life [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         BCCs tend to be more aggressive in patients with NBCCS. Despite this, only a small fraction become locally invasive, and they do so only after puberty [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2241823192">
         <span class="h4">
          Risk factors for basal cell carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although sun exposure is the most important environmental cause of BCC in the general population, the relationship between sun exposure and the development of BCCs in patients with NBCCS is unclear. While ethnicity is a recognized factor affecting the number of BCCs developed by NBCCS patients, with patients with darker skin types developing fewer tumors, the reasons for the variability in the number of BCCs remain largely unknown.
        </p>
        <p>
         The widespread anatomic site distribution of BCCs suggests that frequent sun exposure may not be essential for the development of BCCs in affected patients [
         <a href="#rid53">
          53
         </a>
         ]. However, the observation that there are more tumors on sun-exposed areas suggests that exposure promotes the development of BCCs in patients with NBCCS [
         <a href="#rid56">
          56
         </a>
         ]. A role of sun exposure in the pathogenesis of BCC in patients with NBCCS is supported by the finding that tumors from individuals with a low number of BCCs have fewer somatic ultraviolet (UV)-signature mutations compared with tumors from individuals with a high number of tumors [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         Patients with NBCCS are particularly sensitive to the effects of ionizing radiation, and the development of multiple BCCs within irradiated fields in affected patients is well described [
         <a href="#rid54">
          54,58-61
         </a>
         ]. DNA synthesis is abnormally induced in irradiated NBCCS cells, and this abnormality may supply the subsequent mutation necessary for tumor development in NBCCS patients who have been exposed to ionizing radiation [
         <a href="#rid62">
          62,63
         </a>
         ]. Because of this, radiation therapy is generally avoided in patients with NBCCS.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Odontogenic (jaw) keratocysts
         </span>
         <span class="headingEndMark">
          —
         </span>
         Odontogenic keratocysts (OKCs), also called keratocystic odontogenic tumors, are cystic lesions of the bone that are lined with keratinized epithelium and thought to originate from the dental lamina. Despite their bland histology, these lesions are locally destructive, possibly due to their heparanase expression, which is upregulated [
         <a href="#rid64">
          64
         </a>
         ]. They are neoplastic rather than developmental in origin [
         <a href="#rid65">
          65
         </a>
         ] and are characterized by aggressive clinical behavior, including involvement of the teeth and a high recurrence rate [
         <a href="#rid66">
          66
         </a>
         ]
        </p>
        <p>
         OKCs associated with NBCCS have a different immunophenotype from sporadic keratocysts [
         <a href="#rid67">
          67
         </a>
         ]. In a study of sporadic and NBCCS-associated OKCs, the latter had an increased immunohistochemical expression of the sonic hedgehog proteins Shh, Gli1, and Smo [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         The cysts usually develop after the age of seven and peak during the second or third decades [
         <a href="#rid52">
          52,69
         </a>
         ], but they have been reported in children as young as four [
         <a href="#rid50">
          50
         </a>
         ]. The number of jaw cysts averages six (reported range, 1 to 28), unlike sporadic cases, where they are typically solitary [
         <a href="#rid5">
          5,50
         </a>
         ]. Unlike BCCs, there is no racial predilection [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         Three-fourths of OKCs present in the mandible [
         <a href="#rid50">
          50,71
         </a>
         ]. The most common locations in decreasing frequency are the mandibular third molar region, maxillary third molar region, and mandibular first and second molar region [
         <a href="#rid72">
          72
         </a>
         ]. Approximately one-third are asymptomatic and are detected on routine dental examination, while 50 percent present with jaw swelling, 25 percent with mild pain, and 15 percent with altered taste [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         Treatment is discussed below. (See
         <a class="local">
          'Odontogenic keratocysts'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2843797372">
         <span class="h3">
          Intracranial ectopic calcification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 65 percent of affected persons have calcification of the falx cerebri, but this increases to 80 to 90 percent of those over the age of 40 [
         <a href="#rid50">
          50,74
         </a>
         ]. Other areas of ectopic calcification include the diaphragma sellae in 60 to 80 percent (with complete or partial bridging of the sella turcica), the tentorium cerebelli in 40 percent, and the petroclinoid ligament in 20 percent [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Palmar-plantar pits
         </span>
         <span class="headingEndMark">
          —
         </span>
         Palmar and/or plantar pits are highly characteristic of NBCCS, occurring in approximately 80 percent of affected individuals [
         <a href="#rid50">
          50,76
         </a>
         ]. They are asymptomatic, nonpalpable, shallow depressions (1 to 3 mm) in the skin of the palm and/or soles that are due to partial or complete absence of stratum corneum  (
         <a class="graphic graphic_picture graphicRef72687" href="/z/d/graphic/72687.html" rel="external">
          picture 1
         </a>
         ). They may also be found on the sides, web spaces, and dorsum of the fingers and toes [
         <a href="#rid77">
          77
         </a>
         ]. The differential diagnosis should consider punctate keratoderma, pitted keratolysis, and palmar pits of Darier's disease, but the clinical distinction is usually easy. (See
         <a class="medical medical_review" href="/z/d/html/15504.html" rel="external">
          "Pachyonychia congenita", section on 'Punctate palmoplantar keratoderma type 1'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15462.html" rel="external">
          "Darier disease"
         </a>
         .)
        </p>
        <p>
         Pitting generally develops during the patient's 20s and later but has been reported in much younger patients [
         <a href="#rid54">
          54
         </a>
         ]. In contrast to BCC, there is no racial difference in the frequency of pitting in affected patients with NBCCS [
         <a href="#rid70">
          70
         </a>
         ]. The number of pits is variable but can reach more than 500 in number, particularly in older individuals [
         <a href="#rid77">
          77
         </a>
         ]. They are permanent and do not wax and wane over time. Soaking the hands in water for 10 to 15 minutes can make their appearance more pronounced [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2042629051">
         <span class="h2">
          Minor features
         </span>
        </p>
        <p class="headingAnchor" id="H3653008578">
         <span class="h3">
          Characteristic facies and macrocephaly
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients with NBCCS have a characteristic "coarse" facial appearance consisting of frontal bossing, macrocephaly (80 percent), hypertelorism (5 percent), high-arched eyebrows (40 percent) and palate, widened nasal bridge (60 percent), and mandibular prognathism (35 percent) [
         <a href="#rid5">
          5,50,52,78,79
         </a>
         ]. In 50 to 60 percent of affected individuals, there are milia scattered on the face among the BCCs.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Brain tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medulloblastomas develop in 2 to 5 percent of patients with NBCCS, with a male predominance of 3:1 [
         <a href="#rid47">
          47,80,81
         </a>
         ]. Of note, patients with NBCCS due to
         <em>
          SUFU
         </em>
         mutations have a greatly increased risk of developing a childhood medulloblastoma [
         <a href="#rid3">
          3,12,47
         </a>
         ]. In contrast to sporadic medulloblastomas, which most commonly present between the ages of 6 and 10, medulloblastomas characteristically present by age three in individuals with NBCCS [
         <a href="#rid82">
          82
         </a>
         ]. This syndrome should be considered in any atypically young child with medulloblastoma and in those with tumors with nodular or desmoplastic histology [
         <a href="#rid82">
          82,83
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5218.html" rel="external">
          "Histopathology, genetics, and molecular groups of medulloblastoma"
         </a>
         .)
        </p>
        <p>
         Meningiomas are the next most common brain tumors developing in patients with NBCCS, although they are much less common than medulloblastoma [
         <a href="#rid52">
          52,84
         </a>
         ]. Other tumors and cysts involving the brain have also been reported [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">
          "Epidemiology, pathology, clinical features, and diagnosis of meningioma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28036544">
         <span class="h3">
          Myogenic tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tumors with myogenic differentiation, including fetal rhabdomyoma and rhabdomyosarcoma (RMS), have been reported in a small number of patients with NBCCS [
         <a href="#rid85">
          85
         </a>
         ]. Fetal rhabdomyomas typically arise in children and younger adults, predominantly in the head and neck region, do not metastasize, and are cured by surgical resection alone [
         <a href="#rid86">
          86
         </a>
         ]. RMS is the most common soft tissue sarcoma of childhood and adolescence. It can occur anywhere in the body, but the most common primary sites are the head and neck region and the genitourinary tract [
         <a href="#rid87">
          87
         </a>
         ]. The tumor is locally invasive with high propensity for distant metastasis to lung, bone marrow, and bone. (See
         <a class="medical medical_review" href="/z/d/html/7728.html" rel="external">
          "Rhabdomyosarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1485207029">
         <span class="h3">
          Skeletal abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Occult skeletal abnormalities are frequent in patients with NBCCS and may be associated with a more severe phenotype [
         <a href="#rid88">
          88
         </a>
         ]. Between 38 to 60 percent have rib abnormalities, including bifid ribs, marked widening of the anterior rib ends, and fusion and modeling defects of the ribs [
         <a href="#rid50">
          50,52,89
         </a>
         ]. Occult spina bifida may be seen as a component of NBCCS, although it has not been documented in all series [
         <a href="#rid50">
          50,89
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Cardiac fibromas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac fibromas are increased in frequency in patients with NBCCS, developing in approximately 3 percent of affected individuals [
         <a href="#rid6">
          6
         </a>
         ]. They typically present in infancy. However, late-onset cardiac tumors can develop in a minority of patients [
         <a href="#rid90">
          90
         </a>
         ]. Cardiac fibromas are benign growths, and almost all develop within the ventricular myocardium. Although usually asymptomatic, they can result in impaired left ventricular function and conduction defects, necessitating resection [
         <a href="#rid91">
          91,92
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4881.html" rel="external">
          "Cardiac tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Ovarian fibromas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ovarian fibromas develop in 15 to 25 percent of girls with NBCCS and are often calcified and bilateral [
         <a href="#rid5">
          5,6,50,93
         </a>
         ]. Other ovarian tumors, including fibrosarcomas, are rarely reported [
         <a href="#rid94">
          94
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16833.html" rel="external">
          "Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Lymphomesenteric cysts
         </span>
         <span class="headingEndMark">
          —
         </span>
         Single or multiple lymphomesenteric cysts may be seen as a component of NBCCS [
         <a href="#rid93">
          93
         </a>
         ]. They tend to calcify and are usually asymptomatic.
        </p>
        <p class="headingAnchor" id="H1300118656">
         <span class="h3">
          Ocular anomalies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among the reported ocular anomalies in patients with NBCCS are congenital cataracts, colobomas (involving the choroids and optic nerve), nystagmus, strabismus, hypertelorism, and telecanthus (10 to 25 percent) [
         <a href="#rid6">
          6,50,52
         </a>
         ]. Cleft palate is seen in approximately 5 percent of affected individuals.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Other anomalies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both pectus deformities and Sprengel deformity (narrow sloping shoulders) are more common in individuals with NBCCS [
         <a href="#rid5">
          5,50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4320.html" rel="external">
          "Chest wall diseases and restrictive physiology"
         </a>
         .)
        </p>
        <p>
         Approximately 10 percent of patients have anosmia, which may be a sign of hypogonadotropic hypogonadism. Other hypogonadal features include cryptorchidism, gynecomastia, and scanty facial or body hair [
         <a href="#rid5">
          5,95
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7465.html" rel="external">
          "Isolated gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)"
         </a>
         .)
        </p>
        <p>
         Minor kidney abnormalities, often diagnosed incidentally or at autopsy, are seen in approximately 5 percent of patients with NBCCS [
         <a href="#rid52">
          52
         </a>
         ]. Scattered case reports indicate the occasional association of other neoplasms with NBCCS, including fetal rhabdomyoma [
         <a href="#rid93">
          93,96
         </a>
         ], non-Hodgkin lymphoma [
         <a href="#rid97">
          97
         </a>
         ], Hodgkin lymphoma, melanoma, chronic lymphoid leukemia, soft tissue leiomyosarcoma, breast and lung carcinoma, and sinonasal undifferentiated carcinoma (SNUC) [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H939566762">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of nevoid basal cell carcinoma syndrome (NBCCS) can be established with [
         <a href="#rid48">
          48,99-101
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One major criterion and genetic confirmation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two major criteria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One major criterion and two minor criteria
        </p>
        <p>
        </p>
        <p>
         Major criteria include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One basal cell carcinoma (BCC) under the age of 20 years or multiple BCCs
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Odontogenic keratocyst of the jaw proven by histology in an individual younger than 20 years
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two or more palmar or plantar pits
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lamellar (sheet-like) calcification of the falx cerebri or clear evidence of calcification in an individual younger than age of 20 years
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Childhood medulloblastoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First-degree relative with NBCCS
        </p>
        <p>
        </p>
        <p>
         Minor criteria include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rib anomalies (ie, bifid, fused, or markedly splayed ribs)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macrocephaly
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cleft lip or palate
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other specific skeletal abnormalities (ie, vertebral anomalies, kyphoscoliosis, short fourth metacarpals, postaxial polydactyly)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphomesenteric cysts
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ovarian or cardiac fibroma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ocular anomalies (ie, strabismus, hypertelorism, congenital cataracts, glaucoma, coloboma)
        </p>
        <p>
        </p>
        <p>
         In infants with a family history of NBCCS, early diagnosis may be achieved with the use of screening radiography to look for calcification of the falx, rib anomalies, or calcified ovarian fibromas [
         <a href="#rid5">
          5
         </a>
         ]. However, as individuals with NBCCS are susceptible to X-ray irradiation, the number of radiologic studies should be limited as much as possible, especially in children.
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Diagnostic work-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following studies are indicated in patients suspected of having NBCCS to confirm the diagnosis and assess the disease extent:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skull radiograph or computed tomography (CT) can demonstrate a calcified falx cerebri, complete or partial bridging of the sella turcica, or a broadened nasal root.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Panoramic films are recommended to identify odontogenic keratocysts; magnetic resonance imaging (MRI) may be superior in demonstrating the internal composition and structure of the cysts [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest radiograph to document rib abnormalities (eg, bifid ribs).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hand and foot radiographs show flame-shaped lucencies (lytic bone lesions) in 30 percent of hand films and 17 percent of foot films [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin biopsy of lesions suspicious for BCCs. Histopathologic features of BCC include nodules and/or strands of atypical basaloid cells that show nuclear palisading, cellular apoptosis, and scattered mitotic activity in the dermis  (
         <a class="graphic graphic_picture graphicRef68853 graphicRef79258" href="/z/d/graphic/68853.html" rel="external">
          picture 2A-B
         </a>
         ). Artifactual cleft formation may be seen between the tumor lobules and the surrounding stroma, which may be mucinous. Solar elastosis is usually present in the dermis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2764940664">
         <span class="h2">
          Molecular genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients fulfilling the criteria for clinical diagnosis, the identification of a heterozygous germline
         <em>
          PTCH1
         </em>
         pathogenic variant in lymphocyte DNA confirms the diagnosis of NBCCS [
         <a href="#rid1">
          1
         </a>
         ]. Molecular testing approaches include serial single-gene testing, use of a multigene panel, and more comprehensive genomic testing.
        </p>
        <p>
         If the clinical suspicion is high but no pathogenic variant is found in
         <em>
          PTCH1
         </em>
         or
         <em>
          SUFU
         </em>
         , DNA from two or more different BCCs can be isolated and genetically tested for
         <em>
          PTCH1
         </em>
         and
         <em>
          SMO
         </em>
         using next-generation sequencing to evaluate for postzygotic mosaicism [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3410251667">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of nevoid basal cell carcinoma syndrome (NBCCS) includes a number of syndromes that share some of the NBCCS clinical features, including [
         <a href="#rid103">
          103
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sotos syndrome
         </strong>
         – Sotos syndrome 1 (MIM #117550), or 5q35 deletion syndrome, is an overgrowth syndrome characterized by macrocephaly, characteristic facial features (including bossed forehead and hypertelorism), and skeletal, brain, and cardiac anomalies [
         <a href="#rid104">
          104
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16660.html" rel="external">
          "Microdeletion syndromes (chromosomes 1 to 11)", section on '5q35 deletion syndrome (Sotos syndrome)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bazex syndrome
         </strong>
         – Bazex-Dupré-Christol syndrome (also called Bazex syndrome or follicular atrophoderma and basal cell carcinomas [BCCs]) is an X-linked dominant disorder characterized by congenital hypotrichosis, follicular atrophoderma, milia, and multiple BCCs [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rombo syndrome
         </strong>
         – Rombo syndrome is a genetic syndrome characterized by facial follicular atrophy, atrophoderma vermiculatum, multiple milia, hypotrichosis, peripheral vasodilation with cyanosis, trichoepitheliomas, and predisposition to develop BCCs [
         <a href="#rid106">
          106,107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brooke-Spiegler syndrome
         </strong>
         – Brooke-Spiegler syndrome is a rare autosomal dominant disorder characterized by multiple benign adnexal skin tumors (spiradenoma, cylindroma, and trichoepithelioma) [
         <a href="#rid108">
          108
         </a>
         ]. Histopathologic examination will differentiate these tumors from "nevoid" skin tag-like BCCs in NBCCS. (See
         <a class="medical medical_review" href="/z/d/html/15522.html" rel="external">
          "Brooke-Spiegler syndrome (
          <i>
           CYLD
          </i>
          cutaneous syndrome)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of individuals with nevoid basal cell carcinoma syndrome (NBCCS) requires a multidisciplinary approach. Important issues in the management of affected patients include surveillance for the development of cancers and syndrome-related complications and specific treatment for tumors and odontogenic keratocysts.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals diagnosed with NBCCS are at risk for developing benign and malignant neoplasms and other syndrome-related complications at an early age. The following recommendations based on best available evidence have been proposed for surveillance of patients with NBCCS [
         <a href="#rid100">
          100
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In carriers of
         </strong>
         <strong>
          <em>
           PTCH1
          </em>
         </strong>
         <strong>
          variants (low risk of medulloblastoma)
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Screening for general growth and development at the time of diagnosis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Regular visits to a dermatologist for total body examination annually by age 10, with increased frequency (every three to six months) after the first basal cell carcinoma (BCC) is diagnosed
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dental examination and screening for odontogenic keratocyst (OKC) with orthopantogram or MRI starting at age 8 and every two years thereafter, if no abnormalities are detected, or annually after the detection of the first OKC
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Baseline cardiac ultrasound at the time of diagnosis, repeated if indicated
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Baseline ophthalmologic examination, including an ocular pressure, repeated if indicated beginning at age 8
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No brain MRI screening for medulloblastoma unless concerning neurologic examination, head circumference change, or other unusual signs or symptoms
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In carriers of
         </strong>
         <strong>
          <em>
           SUFU
          </em>
         </strong>
         <strong>
          variants (high risk of medulloblastoma)
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Same as
         <em>
          PTCH1
         </em>
         mutation carriers, with the exception of no jaw radiographs, as OKCs have not been described
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Baseline brain MRI for medulloblastoma screening every four months until the age of 3 years and then every six months until age 5
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Treatment of basal cell carcinomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the large number of lesions, treatment of basal cell carcinomas (BCCs) in patients with NBCCS may be extremely difficult.
        </p>
        <p>
         There is no evidence-based approach to the management of multiple lesions in patients with NBCCS, and the treatment options are the same as for sporadic BCC. (See
         <a class="medical medical_review" href="/z/d/html/5338.html" rel="external">
          "Treatment and prognosis of basal cell carcinoma at low risk of recurrence"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13724.html" rel="external">
          "Treatment of basal cell carcinomas at high risk for recurrence"
         </a>
         .)
        </p>
        <p>
         Surgical excision is the first-line therapy for lesions that are limited in number and for fast-growing lesions. For locally aggressive tumors and for those located in high-risk areas, Mohs micrographic surgery is preferable to conventional excision. (See
         <a class="medical medical_review" href="/z/d/html/13724.html" rel="external">
          "Treatment of basal cell carcinomas at high risk for recurrence"
         </a>
         .)
        </p>
        <p>
         As multiple surgical excisions are often a source of discomfort, pain, and disfigurement for patients with NBCCS, alternative surgical and nonsurgical approaches can be valuable options in patients with numerous small, nodular tumors or superficial tumors. These include curettage and electrodesiccation (C&amp;E), laser therapy, topical therapies, and photodynamic therapy (PDT) (see
         <a class="medical medical_review" href="/z/d/html/5338.html" rel="external">
          "Treatment and prognosis of basal cell carcinoma at low risk of recurrence"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         C&amp;E is most appropriate for low-risk, superficial or nodular BCCs on the trunk or extremities but is not recommended for BCCs with clinical and histologic features that suggest an elevated risk for tumor recurrence [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Carbon dioxide laser therapy can be a useful modality in selected patients for tumors in low-risk areas and has shown efficacy in combination with microscopically controlled excision (Mohs micrographic surgery) [
         <a href="#rid110">
          110-114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Superficial lesions can be treated with 5% topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         or
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         5% cream. In several reports, imiquimod 5% cream applied three days per week has shown considerable efficacy for superficial BCCs in affected patients [
         <a href="#rid115">
          115-120
         </a>
         ]. Imiquimod is less effective for nodular BCCs [
         <a href="#rid115">
          115
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is increasing experience with PDT in patients with NBCCS [
         <a href="#rid121">
          121,122
         </a>
         ]. As with sporadic BCCs, PDT appears most effective for superficial lesions [
         <a href="#rid114">
          114
         </a>
         ]. One of the advantages of PDT is that multiple contiguous BCCs can be treated in one session. (See
         <a class="medical medical_review" href="/z/d/html/5338.html" rel="external">
          "Treatment and prognosis of basal cell carcinoma at low risk of recurrence", section on 'Photodynamic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiation therapy is
         <strong>
          not
         </strong>
         recommended for the treatment of BCC in patients with NBCCS, given their sensitivity to ionizing radiations and the risk of induction of new BCCs.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1960994010">
         <span class="h2">
          Locally advanced and metastatic basal cell carcinomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          Vismodegib
         </a>
         and
         <a class="drug drug_general" data-topicid="103072" href="/z/d/drug information/103072.html" rel="external">
          sonidegib
         </a>
         , oral small-molecule inhibitors of Smoothened (SMO) that block the activation of the sonic hedgehog (SHH) pathway, offer a new approach for patients with metastatic disease or for patients who are no longer amenable to local therapy [
         <a href="#rid123">
          123,124
         </a>
         ].
        </p>
        <p>
         A randomized trial including 41 patients with NBCCS found that
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          vismodegib
         </a>
         was more effective than placebo in slowing the rate of BCC development and reducing tumor burden [
         <a href="#rid125">
          125
         </a>
         ]. In this trial, patients were treated with either 150 mg per day of vismodegib (n = 26) or placebo (n = 15) for 1 to 15 months (mean, 8 months). At three months, a significantly lower mean per-patient incidence of new, surgically eligible BCCs was detected in the active treatment group than in the placebo group (2 versus 29 BCCs per year). In addition, tumor size decreased to a greater extent in patients who received vismodegib than in those who received placebo, with a few patients achieving complete remission. Adverse effects of vismodegib included loss of taste, muscle cramps, hair loss, and weight loss and led to treatment discontinuation in 14 of 26 patients (54 percent). In addition, tumors regrew following drug discontinuation. In the subsequent, open-label phase, 37 patients continued vismodegib for up to 36 months [
         <a href="#rid126">
          126
         </a>
         ]. In the 11 patients initially assigned to placebo, vismodegib reduced the development of new surgically eligible BCCs compared with placebo (0.4 versus 30 BCCs per year). However, only a few patients tolerated vismodegib continuously for the full 36 months.
        </p>
        <p>
         Regrowth of tumors despite continued therapy has also been reported in patients with tumors that had initially responded to
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          vismodegib
         </a>
         [
         <a href="#rid127">
          127,128
         </a>
         ]. In a series of 28 patients (including 5 patients with NBCCS) with a total of 230 advanced and nonadvanced BCCs, tumor regrowth during treatment was detected in 6 patients (21 percent) and affected 5 percent of all tumors [
         <a href="#rid127">
          127
         </a>
         ]. The mean time to tumor regrowth was 56 weeks. The reason for this occurrence is unknown. (See
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies", section on 'Vismodegib'
         </a>
         .)
        </p>
        <p>
         Oral
         <a class="drug drug_general" data-topicid="103072" href="/z/d/drug information/103072.html" rel="external">
          sonidegib
         </a>
         at a daily dose of 200 mg has shown a similar efficacy as
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          vismodegib
         </a>
         in the treatment of locally advanced or metastatic BCC [
         <a href="#rid124">
          124,129-131
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies", section on 'Sonidegib'
         </a>
         .)
        </p>
        <p>
         Topical
         <a class="drug drug_general" data-topicid="103072" href="/z/d/drug information/103072.html" rel="external">
          sonidegib
         </a>
         was evaluated in a randomized trial in which 27 BCCs in eight patients with NBCCS were treated with topical sonidegib or vehicle twice daily for four weeks [
         <a href="#rid132">
          132
         </a>
         ]. Complete or partial responses were observed in 12 out of 13 lesions treated with sonidegib compared with 1 out of 14 lesions treated with placebo.
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Prevention of basal cell carcinomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with NBCCS should be counseled to minimize exposure to ultraviolet light and avoid therapeutic and diagnostic ionizing irradiation (eg, MRI is preferred over computed tomography [CT]), if at all possible [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Oral
         <a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">
          nicotinamide
         </a>
         (vitamin B3), a dietary supplement available over the counter, at the dose of 500 mg twice daily was evaluated for the prevention of nonmelanoma skin cancer in a phase III randomized trial including 386 participants who had had at least two skin cancers in the previous five years [
         <a href="#rid133">
          133
         </a>
         ]. At 12 months, the rate of new BCCs was 20 percent lower in the nicotinamide group compared with the placebo group.
        </p>
        <p>
         Oral retinoids (
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         and
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         ) have shown some efficacy for the chemoprevention of nonmelanoma skin cancers in high-risk populations [
         <a href="#rid134">
          134,135
         </a>
         ]. However, there are no studies evaluating the efficacy of systemic retinoids as chemopreventive agents for patients with NBCCS. At least one report suggests that low-dose isotretinoin (10 mg daily) is ineffective in preventing additional BCCs in patients who have had two or more sporadic BCCs [
         <a href="#rid136">
          136
         </a>
         ]. Because of the need for moderate to high doses, the limited degree of benefit, and their adverse effects, oral retinoids are seldom used. (See
         <a class="medical medical_review" href="/z/d/html/16339.html" rel="external">
          "Prevention and management of skin cancer in solid organ transplant recipients", section on 'Acitretin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h2">
          Odontogenic keratocysts
         </span>
        </p>
        <p class="headingAnchor" id="H2125728686">
         <span class="h3">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of choice is wide surgical excision and curettage with extraction of associated teeth by an experienced oral-maxillofacial surgeon or otolaryngologist [
         <a href="#rid5">
          5,52
         </a>
         ]. Bone and alveolar nerve grafting may be required in some instances. A 10-year retrospective review of 83 cases of odontogenic keratocysts suggests that marsupialization followed by enucleation results in the lowest recurrence rate [
         <a href="#rid137">
          137
         </a>
         ]. Histopathologic examination of tissue is important because several cases of malignant transformation to squamous cell carcinoma have been reported [
         <a href="#rid138">
          138-140
         </a>
         ].
        </p>
        <p>
         Recurrence can result from incomplete removal, remnants of dental lamina within the jaw, or the presence of satellite cysts. In a review of over 6000 sporadic and syndromic keratocysts treated with various surgical techniques, the recurrence rate for those associated with NBCCS was 35 percent [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3750832464">
         <span class="h3">
          Vismodegib
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reduction in size or resolution of odontogenic keratocysts has been reported in some patients with NBCCS treated with
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          vismodegib
         </a>
         , an oral inhibitor of the HH pathway approved for the treatment of advanced BCC [
         <a href="#rid141">
          141
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies", section on 'Vismodegib'
         </a>
         .)
        </p>
        <p>
         A series of six patients with nine odontogenic keratocysts for whom baseline MRI was available were treated with
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          vismodegib
         </a>
         150 mg per day for 11 to 24 months [
         <a href="#rid142">
          142
         </a>
         ]. Post-treatment MRI showed a 50 percent reduction of the longest diameter of keratocysts in four of six patients. In one patient with complete resolution of one lesion, there was no recurrence nine months after drug cessation. All patients experienced mild to moderate adverse effects of taste loss, muscle cramps, and hair loss; three patients required a brief drug break.
        </p>
        <p>
         However, additional studies are necessary to determine the role, long-term efficacy, and maintenance regimen of
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          vismodegib
         </a>
         for the treatment of odontogenic keratocysts.
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h2">
          Medulloblastomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with NBCCS, radiation therapy for medulloblastomas induces hundreds of difficult to manage BCCs and should be avoided [
         <a href="#rid59">
          59,143
         </a>
         ]. The management of medulloblastoma is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/88801.html" rel="external">
          "Treatment and prognosis of medulloblastoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7649457">
         <span class="h2">
          Vitamin D deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with NBCCS who adopt strict sun protection measures have an increased risk for vitamin D deficiency and may require vitamin D supplementation. In a retrospective cohort study of 41 patients with NBCCS, the prevalence of vitamin D deficiency (25[OH]D level ≤20 ng/mL) was significantly greater than that reported in the general population (56 versus 18 percent) [
         <a href="#rid144">
          144
         </a>
         ]. Thus, clinicians should be aware of the potential for vitamin D deficiency in patients with NBCCS. (See
         <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">
          "Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3986954788">
         <span class="h1">
          GENETIC COUNSELING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Referral to a geneticist for counseling is advised for patients and families with nevoid basal cell carcinoma syndrome (NBCCS). Approximately 70 to 80 percent of individuals diagnosed with NBCCS have an affected parent [
         <a href="#rid1">
          1
         </a>
         ]. Since NBCCS is an autosomal dominant disorder, the offspring have a 50 percent risk of inheriting the
         <em>
          PTCH1
         </em>
         or
         <em>
          SUFU
         </em>
         pathogenic variant.
        </p>
        <p>
         An updated genetic consultation is recommended prior to childbearing years, so that the affected individual can better understand their own reproductive risks and options. Early referral for genetics consultation prior to pregnancy and planning of pregnancies is recommended for couples interested in prenatal diagnosis.
        </p>
        <p class="headingAnchor" id="H2726639505">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nevoid basal cell carcinoma syndrome (NBCCS) is generally not associated with increased mortality. However, the prognosis is guarded for those with metastatic basal cell carcinoma (BCC) or medulloblastoma.
        </p>
        <p class="headingAnchor" id="H4054329564">
         <span class="h1">
          ONLINE RESOURCES AND SUPPORT GROUPS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several online resources and patient organizations can provide information and support for patients and families with nevoid basal cell carcinoma syndrome (NBCCS):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgorlingroup.org%2F&amp;token=j2JzKj3gPtgdhxo7n9F3q9Q6xnMCzgmjJ4YLpnN0L62vALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=5340" target="_blank">
          The Gorlin Syndrome Group
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgorlinsyndrome.org%2F&amp;token=j2JzKj3gPtgdhxo7n9F3q6Ri%2FeQ5ZA27YNofOK6svuzuof9jBIQYxjNQRwQlVULL&amp;TOPIC_ID=5340" target="_blank">
          The Gorlin Syndrome Alliance
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgorlinsyndromesupportaustralia.weebly.com%2F&amp;token=%2B4RE0IS3cvAK0C7ohvHtHp75t42hBRqnVkKKulgInzKGUmllf2Ym0c9jJlCLtDFE4256y2UEFFePqFzb5xGQDw%3D%3D&amp;TOPIC_ID=5340" target="_blank">
          The Australian Gorlin Syndrome Mutual Support Group
         </a>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and pathogenesis
         </strong>
         – Nevoid basal cell carcinoma syndrome (NBCCS) is a rare autosomal dominant, multisystem, tumor-predisposing disorder caused by germline pathogenic variants in the
         <em>
          PTCH1
         </em>
         or
         <em>
          SUFU
         </em>
         tumor suppressor genes. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The primary manifestation of NBCCS is the development of multiple basal cell carcinomas (BCCs), which are histologically identical to sporadic BCCs. NBCCS is also associated with a variety of other benign and malignant tumors, including odontogenic keratocysts, cardiac and ovarian fibromas, and medulloblastomas. Other features include palmar and plantar pits, craniofacial and skeletal abnormalities, ocular abnormalities, and ectopic intracranial calcifications. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of NBCCS is established in patients who fulfill two major clinical criteria or one major and two minor clinical criteria. The identification of germline pathogenic variants in
         <em>
          PTCH1
         </em>
         or
         <em>
          SUFU
         </em>
         by molecular genetic testing confirms the diagnosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The management of individuals with NBCCS requires a multidisciplinary approach. Important issues in the management of affected patients include surveillance for the development of cancers and syndrome-related complications starting in early childhood and specific treatment for tumors and odontogenic keratocysts. (See
         <a class="local">
          'Management'
         </a>
         above and
         <a class="local">
          'Surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Basal cell carcinoma treatment
         </strong>
         – The management of BCCs can be particularly difficult, due to the multiplicity of lesions and the need for multiple procedures.
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          Vismodegib
         </a>
         and
         <a class="drug drug_general" data-topicid="103072" href="/z/d/drug information/103072.html" rel="external">
          sonidegib
         </a>
         , oral small-molecule inhibitors of the sonic hedgehog pathway, are a therapeutic option for patients with locally advanced and metastatic BCCs. (See
         <a class="local">
          'Treatment of basal cell carcinomas'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies", section on 'Initial therapy (hedgehog pathway inhibitors)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H881525020">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Gary Goldenberg, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Evans DG, Farndon PA. Nevoid basal cell carcinoma syndrome. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, Seattle (WA) 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           GORLIN RJ, GOLTZ RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med 1960; 262:908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MJ, Beetz C, Williams SG, et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 2014; 32:4155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen MM Jr. Nevoid basal cell carcinoma syndrome: molecular biology and new hypotheses. Int J Oral Maxillofac Surg 1999; 28:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shanley S, Ratcliffe J, Hockey A, et al. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet 1994; 50:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans DG, Ladusans EJ, Rimmer S, et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet 1993; 30:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010; 152A:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson DE, Taylor WB, Falls HF, Davidson RT. The nevoid basal cell carcinoma syndrome. Am J Hum Genet 1967; 19:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujii K, Ohashi H, Suzuki M, et al. Frameshift mutation in the PTCH2 gene can cause nevoid basal cell carcinoma syndrome. Fam Cancer 2013; 12:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan Z, Li J, Du J, et al. A missense mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family. J Med Genet 2008; 45:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu LL, Li TJ. [PTCH2 gene alterations in keratocystic odontogenic tumors associated with nevoid basal cell carcinoma syndrome]. Beijing Da Xue Xue Bao Yi Xue Ban 2008; 40:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans DG, Oudit D, Smith MJ, et al. First evidence of genotype-phenotype correlations in Gorlin syndrome. J Med Genet 2017; 54:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farndon PA, Del Mastro RG, Evans DG, Kilpatrick MW. Location of gene for Gorlin syndrome. Lancet 1992; 339:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272:1668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unden AB, Holmberg E, Lundh-Rozell B, et al. Mutations in the human homologue of Drosophila patched (PTCH) in basal cell carcinomas and the Gorlin syndrome: different in vivo mechanisms of PTCH inactivation. Cancer Res 1996; 56:4562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein AM, Stewart C, Bale AE, et al. Localization of the gene for the nevoid basal cell carcinoma syndrome. Am J Hum Genet 1994; 54:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam CW, Leung CY, Lee KC, et al. Novel mutations in the PATCHED gene in basal cell nevus syndrome. Mol Genet Metab 2002; 76:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aszterbaum M, Rothman A, Johnson RL, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol 1998; 110:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wicking C, Shanley S, Smyth I, et al. Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident. Am J Hum Genet 1997; 60:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang H, Ping XL, Lee PK, et al. Role of PTCH and p53 genes in early-onset basal cell carcinoma. Am J Pathol 2001; 158:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teh MT, Blaydon D, Chaplin T, et al. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res 2005; 65:8597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gailani MR, Ståhle-Bäckdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996; 14:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolter M, Reifenberger J, Sommer C, et al. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1997; 57:2581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodak N, Queille S, Avril MF, et al. High levels of patched gene mutations in basal-cell carcinomas from patients with xeroderma pigmentosum. Proc Natl Acad Sci U S A 1999; 96:5117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Errico M, Calcagnile A, Canzona F, et al. UV mutation signature in tumor suppressor genes involved in skin carcinogenesis in xeroderma pigmentosum patients. Oncogene 2000; 19:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levanat S, Gorlin RJ, Fallet S, et al. A two-hit model for developmental defects in Gorlin syndrome. Nat Genet 1996; 12:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 2011; 476:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gailani MR, Bale AE. Developmental genes and cancer: role of patched in basal cell carcinoma of the skin. J Natl Cancer Inst 1997; 89:1103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Booth DR. The hedgehog signalling pathway and its role in basal cell carcinoma. Cancer Metastasis Rev 1999; 18:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grachtchouk V, Grachtchouk M, Lowe L, et al. The magnitude of hedgehog signaling activity defines skin tumor phenotype. EMBO J 2003; 22:2741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dahmane N, Lee J, Robins P, et al. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature 1997; 389:876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz i Altaba A, Sánchez P, Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2002; 2:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghali L, Wong ST, Green J, et al. Gli1 protein is expressed in basal cell carcinomas, outer root sheath keratinocytes and a subpopulation of mesenchymal cells in normal human skin. J Invest Dermatol 1999; 113:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alcedo J, Ayzenzon M, Von Ohlen T, et al. The Drosophila smoothened gene encodes a seven-pass membrane protein, a putative receptor for the hedgehog signal. Cell 1996; 86:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eichberger T, Regl G, Ikram MS, et al. FOXE1, a new transcriptional target of GLI2 is expressed in human epidermis and basal cell carcinoma. J Invest Dermatol 2004; 122:1180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green J, Leigh IM, Poulsom R, Quinn AG. Basal cell carcinoma development is associated with induction of the expression of the transcription factor Gli-1. Br J Dermatol 1998; 139:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wicking C, Smyth I, Bale A. The hedgehog signalling pathway in tumorigenesis and development. Oncogene 1999; 18:7844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duman-Scheel M, Weng L, Xin S, Du W. Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature 2002; 417:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skoda AM, Simovic D, Karin V, et al. The role of the Hedgehog signaling pathway in cancer: A comprehensive review. Bosn J Basic Med Sci 2018; 18:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oro AE, Higgins KM, Hu Z, et al. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 1997; 276:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagano T, Bito T, Kallassy M, et al. Overexpression of the human homologue of Drosophila patched (PTCH) in skin tumours: specificity for basal cell carcinoma. Br J Dermatol 1999; 140:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zedan W, Robinson PA, Markham AF, High AS. Expression of the Sonic Hedgehog receptor "PATCHED" in basal cell carcinomas and odontogenic keratocysts. J Pathol 2001; 194:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohki K, Kumamoto H, Ichinohasama R, et al. PTC gene mutations and expression of SHH, PTC, SMO, and GLI-1 in odontogenic keratocysts. Int J Oral Maxillofac Surg 2004; 33:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 2018; 19:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones EA, Sajid MI, Shenton A, Evans DG. Basal cell carcinomas in gorlin syndrome: a review of 202 patients. J Skin Cancer 2011; 2011:217378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacDonald DS. A systematic review of the literature of nevoid basal cell carcinoma syndrome affecting East Asians and North Europeans. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997; 69:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yasar B, Byers HJ, Smith MJ, et al. Common variants modify the age of onset for basal cell carcinomas in Gorlin syndrome. Eur J Hum Genet 2015; 23:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 1987; 66:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solis DC, Kwon GP, Ransohoff KJ, et al. Risk Factors for Basal Cell Carcinoma Among Patients With Basal Cell Nevus Syndrome: Development of a Basal Cell Nevus Syndrome Patient Registry. JAMA Dermatol 2017; 153:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howell JB. Nevoid basal cell carcinoma syndrome. Profile of genetic and environmental factors in oncogenesis. J Am Acad Dermatol 1984; 11:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huq AJ, Bogwitz M, Gorelik A, et al. Cohort study of Gorlin syndrome with emphasis on standardised phenotyping and quality of life assessment. Intern Med J 2017; 47:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein AM, Bale SJ, Peck GL, DiGiovanna JJ. Sun exposure and basal cell carcinomas in the nevoid basal cell carcinoma syndrome. J Am Acad Dermatol 1993; 29:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiang A, Jaju PD, Batra P, et al. Genomic Stability in Syndromic Basal Cell Carcinoma. J Invest Dermatol 2018; 138:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frentz G, Munch-Petersen B, Wulf HC, et al. The nevoid basal cell carcinoma syndrome: sensitivity to ultraviolet and x-ray irradiation. J Am Acad Dermatol 1987; 17:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Malley S, Weitman D, Olding M, Sekhar L. Multiple neoplasms following craniospinal irradiation for medulloblastoma in a patient with nevoid basal cell carcinoma syndrome. Case report. J Neurosurg 1997; 86:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wollenberg A, Peter RU, Przybilla B. Multiple superficial basal cell carcinomas (basalomatosis) following cobalt irradiation. Br J Dermatol 1995; 133:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stavrou T, Bromley CM, Nicholson HS, et al. Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 2001; 23:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujii K, Suzuki N, Ishijima S, et al. Abnormal DNA synthesis activity induced by X-rays in nevoid basal cell carcinoma syndrome cells. Biochem Biophys Res Commun 1997; 240:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mancuso M, Pazzaglia S, Tanori M, et al. Basal cell carcinoma and its development: insights from radiation-induced tumors in Ptch1-deficient mice. Cancer Res 2004; 64:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katase N, Nagatsuka H, Tsujigiwa H, et al. Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor. J Oral Pathol Med 2007; 36:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agaram NP, Collins BM, Barnes L, et al. Molecular analysis to demonstrate that odontogenic keratocysts are neoplastic. Arch Pathol Lab Med 2004; 128:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chrcanovic BR, Gomez RS. Recurrence probability for keratocystic odontogenic tumors: An analysis of 6427 cases. J Craniomaxillofac Surg 2017; 45:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolár Z, Geierová M, Bouchal J, et al. Immunohistochemical analysis of the biological potential of odontogenic keratocysts. J Oral Pathol Med 2006; 35:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoyos Cadavid AM, Kaminagakura E, Rodrigues MFSD, et al. Immunohistochemical evaluation of Sonic Hedgehog signaling pathway proteins (Shh, Ptch1, Ptch2, Smo, Gli1, Gli2, and Gli3) in sporadic and syndromic odontogenic keratocysts. Clin Oral Investig 2019; 23:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howell JB, Anderson DE. "The basal-cell nevus" by Howell and Caro, January 1959. Commentary: The nevoid basal cell carcinoma syndrome. Arch Dermatol 1982; 118:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein AM, Pastakia B, DiGiovanna JJ, et al. Clinical findings in two African-American families with the nevoid basal cell carcinoma syndrome (NBCC). Am J Med Genet 1994; 50:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myoung H, Hong SP, Hong SD, et al. Odontogenic keratocyst: Review of 256 cases for recurrence and clinicopathologic parameters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brannon RB. The odontogenic keratocyst. A clinicopathologic study of 312 cases. Part I. Clinical features. Oral Surg Oral Med Oral Pathol 1976; 42:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chenevix-Trench G, Wicking C, Berkman J, et al. Further localization of the gene for nevoid basal cell carcinoma syndrome (NBCCS) in 15 Australasian families: linkage and loss of heterozygosity. Am J Hum Genet 1993; 53:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratcliffe JF, Shanley S, Ferguson J, Chenevix-Trench G. The diagnostic implication of falcine calcification on plain skull radiographs of patients with basal cell naevus syndrome and the incidence of falcine calcification in their relatives and two control groups. Br J Radiol 1995; 68:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunnick NR, Head GL, Peck GL, Yoder FW. Nevoid basal cell carcinoma syndrome: radiographic manifestations including cystlike lesions of the phalanges. Radiology 1978; 127:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutierrez MM, Mora RG. Nevoid basal cell carcinoma syndrome. A review and case report of a patient with unilateral basal cell nevus syndrome. J Am Acad Dermatol 1986; 15:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howell JB, Mehregan AH. Pursuit of the pits in the nevoid basal cell carcinoma syndrome. Arch Dermatol 1970; 102:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahbari H, Mehregan AH. Basal cell epithelioma (carcinoma) in children and teenagers. Cancer 1982; 49:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Southwick GJ, Schwartz RA. The basal cell nevus syndrome: disasters occurring among a series of 36 patients. Cancer 1979; 44:2294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans DG, Farndon PA, Burnell LD, et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991; 64:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacombe D, Chateil JF, Fontan D, Battin J. Medulloblastoma in the nevoid basal-cell carcinoma syndrome: case reports and review of the literature. Genet Couns 1990; 1:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amlashi SF, Riffaud L, Brassier G, Morandi X. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer 2003; 98:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brugières L, Remenieras A, Pierron G, et al. High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. J Clin Oncol 2012; 30:2087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortimer PS, Geaney DP, Liddell K, Dawber RP. Basal cell naevus syndrome and intracranial meningioma. J Neurol Neurosurg Psychiatry 1984; 47:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hettmer S, Teot LA, Kozakewich H, et al. Myogenic tumors in nevoid Basal cell carcinoma syndrome. J Pediatr Hematol Oncol 2015; 37:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh SN, Hurt MA. Cutaneous fetal rhabdomyoma: a case report and historical review of the literature. Am J Surg Pathol 2008; 32:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang C. Childhood rhabdomyosarcoma: recent advances and prospective views. J Dent Res 2012; 91:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Betancourt NJ, Qian MF, Pickford JR, et al. Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease Severity. J Clin Oncol 2022; 40:2119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratcliffe JF, Shanley S, Chenevix-Trench G. The prevalence of cervical and thoracic congenital skeletal abnormalities in basal cell naevus syndrome; a review of cervical and chest radiographs in 80 patients with BCNS. Br J Radiol 1995; 68:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szczałuba K, Makuła E, Piórecka-Makuła A, et al. Intracardiac tumor as a rare manifestation of genetic syndromes-presentation of a family with Gorlin syndrome and a literature review. J Appl Genet 2020; 61:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones KL, Wolf PL, Jensen P, et al. The Gorlin syndrome: a genetically determined disorder associated with cardiac tumor. Am Heart J 1986; 111:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho JM, Danielson GK, Puga FJ, et al. Surgical resection of ventricular cardiac fibromas: early and late results. Ann Thorac Surg 2003; 76:1929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol Clin 1995; 13:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraemer BB, Silva EG, Sneige N. Fibrosarcoma of ovary. A new component in the nevoid basal-cell carcinoma syndrome. Am J Surg Pathol 1984; 8:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace DC, Murphy KJ, Kelly L, Ward WH. The basal cell naevus syndrome. Report of a family with anosmia and a case of hypogonadotrophic hypopituitarism. J Med Genet 1973; 10:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiSanto S, Abt AB, Boal DK, Krummel TM. Fetal rhabdomyoma and nevoid basal cell carcinoma syndrome. Pediatr Pathol 1992; 12:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pereira CM, Lopes AP, Meneghini AJ, et al. Oral diffuse B-cell non-Hodgkin's lymphoma associated to Gorlin-Goltz syndrome: a case report with one year follow-up. Indian J Pathol Microbiol 2011; 54:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobota A, Pena M, Santi M, Ali Ahmed A. Undifferentiated sinonasal carcinoma in a patient with nevoid basal cell carcinoma syndrome. Int J Surg Pathol 2007; 15:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bree AF, Shah MR, BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet A 2011; 155A:2091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verkouteren BJA, Cosgun B, Reinders MGHC, et al. A guideline for the clinical management of basal cell naevus syndrome (Gorlin-Goltz syndrome). Br J Dermatol 2022; 186:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold NB, Campbell IM, Sheppard SE, Tan WH. Proposed criteria for nevoid basal cell carcinoma syndrome in children assessed using statistical optimization. Sci Rep 2021; 11:19791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palacios E, Serou M, Restrepo S, Rojas R. Odontogenic keratocysts in nevoid basal cell carcinoma (Gorlin's) syndrome: CT and MRI evaluation. Ear Nose Throat J 2004; 83:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schierbeck J, Vestergaard T, Bygum A. Skin Cancer Associated Genodermatoses: A Literature Review. Acta Derm Venereol 2019; 99:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edmondson AC, Kalish JM. Overgrowth Syndromes. J Pediatr Genet 2015; 4:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torrelo A, Sprecher E, Mediero IG, et al. What syndrome is this? Bazex-Dupre-Christol syndrome. Pediatr Dermatol 2006; 23:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaëlsson G, Olsson E, Westermark P. The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis. Acta Derm Venereol 1981; 61:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Steensel MA, Jaspers NG, Steijlen PM. A case of Rombo syndrome. Br J Dermatol 2001; 144:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kazakov DV. Brooke-Spiegler Syndrome and Phenotypic Variants: An Update. Head Neck Pathol 2016; 10:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blixt E, Nelsen D, Stratman E. Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone. Dermatol Surg 2013; 39:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doctoroff A, Oberlender SA, Purcell SM. Full-face carbon dioxide laser resurfacing in the management of a patient with the nevoid basal cell carcinoma syndrome. Dermatol Surg 2003; 29:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nouri K, Chang A, Trent JT, Jiménez GP. Ultrapulse CO2 used for the successful treatment of basal cell carcinomas found in patients with basal cell nevus syndrome. Dermatol Surg 2002; 28:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grobbelaar AO, Horlock N, Gault DT. Gorlin's syndrome: the role of the carbon dioxide laser in patient management. Ann Plast Surg 1997; 39:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krunic AL, Viehman GE, Madani S, Clark RE. Microscopically controlled surgical excision combined with ultrapulse CO2 vaporization in the management of a patient with the nevoid basal cell carcinoma syndrome. J Dermatol 1998; 25:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopera D, Cerroni L, Fink-Puches R, Kerl H. Different treatment modalities for the management of a patient with the nevoid basal cell carcinoma syndrome. J Am Acad Dermatol 1996; 34:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Micali G, De Pasquale R, Caltabiano R, et al. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report. J Dermatolog Treat 2002; 13:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stockfleth E, Ulrich C, Hauschild A, et al. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol 2002; 12:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Micali G, Lacarrubba F, Nasca MR, De Pasquale R. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome. Clin Exp Dermatol 2003; 28 Suppl 1:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg 2000; 26:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vereecken P, Monsieur E, Petein M, Heenen M. Topical application of imiquimod for the treatment of high-risk facial basal cell carcinoma in Gorlin syndrome. J Dermatolog Treat 2004; 15:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreres JR, Macaya A, Jucglà A, et al. Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream. J Eur Acad Dermatol Venereol 2006; 20:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapas AM, Gilchrest BA. Broad area photodynamic therapy for treatment of multiple basal cell carcinomas in a patient with nevoid basal cell carcinoma syndrome. J Drugs Dermatol 2006; 5:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Itkin A, Gilchrest BA. delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. Dermatol Surg 2004; 30:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008; 8:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dummer R, Ascierto PA, Basset-Seguin N, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol 2020; 34:1944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366:2180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang JY, Ally MS, Chanana AM, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2016; 17:1720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol 2012; 148:1324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang AL, Atwood SX, Tartar DM, Oro AE. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. JAMA Dermatol 2013; 149:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie P, Lefrançois P. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis. J Am Acad Dermatol 2018; 79:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 2015; 16:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol 2018; 32:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011; 131:1735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med 2015; 373:1618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 2005; 152:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraemer KH, DiGiovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318:1633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tangrea JA, Edwards BK, Taylor PR, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst 1992; 84:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habibi A, Saghravanian N, Habibi M, et al. Keratocystic odontogenic tumor: a 10-year retrospective study of 83 cases in an Iranian population. J Oral Sci 2007; 49:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand VK, Arrowood JP Jr, Krolls SO. Malignant potential of the odontogenic keratocyst. Otolaryngol Head Neck Surg 1994; 111:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenberg D, Sciubba J, Koch W, Tufano RP. Malignant odontogenic tumors: a 22-year experience. Laryngoscope 2004; 114:1770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheer M, Koch AM, Drebber U, Kübler AC. Primary intraosseous carcinoma of the jaws arising from an odontogenic cyst--a case report. J Craniomaxillofac Surg 2004; 32:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg LH, Landau JM, Moody MN, et al. Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449. Arch Dermatol 2011; 147:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ally MS, Tang JY, Joseph T, et al. The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome. JAMA Dermatol 2014; 150:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter AW, Pivnick EK, Bale AE, Kun LE. Complications of the nevoid basal cell carcinoma syndrome: a case report. J Pediatr Hematol Oncol 1997; 19:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang JY, Wu A, Linos E, et al. High prevalence of vitamin D deficiency in patients with basal cell nevus syndrome. Arch Dermatol 2010; 146:1105.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5340 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Evans DG, Farndon PA. Nevoid basal cell carcinoma syndrome. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, Seattle (WA) 1993.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13851319" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25403219" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10355946" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Nevoid basal cell carcinoma syndrome: molecular biology and new hypotheses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8042673" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Nevoid basal cell carcinoma syndrome: review of 118 affected individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8326488" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20082463" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4960000" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23479190" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Frameshift mutation in the PTCH2 gene can cause nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18285427" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A missense mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18278130" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : [PTCH2 gene alterations in keratocystic odontogenic tumors associated with nevoid basal cell carcinoma syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28596197" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : First evidence of genotype-phenotype correlations in Gorlin syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1347096" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Location of gene for Gorlin syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8681379" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8658145" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Human homolog of patched, a candidate gene for the basal cell nevus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8840960" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mutations in the human homologue of Drosophila patched (PTCH) in basal cell carcinomas and the Gorlin syndrome: different in vivo mechanisms of PTCH inactivation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7909984" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Localization of the gene for the nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12175781" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Novel mutations in the PATCHED gene in basal cell nevus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9620294" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8981943" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11159175" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Role of PTCH and p53 genes in early-onset basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16204023" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8782823" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9205058" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10220428" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : High levels of patched gene mutations in basal-cell carcinomas from patients with xeroderma pigmentosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10656695" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : UV mutation signature in tumor suppressor genes involved in skin carcinogenesis in xeroderma pigmentosum patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8528259" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A two-hit model for developmental defects in Gorlin syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5279523" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Mutation and cancer: statistical study of retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21833082" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A continuum model for tumour suppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9262247" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Developmental genes and cancer: role of patched in basal cell carcinoma of the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10728988" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The hedgehog signalling pathway and its role in basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12773389" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The magnitude of hedgehog signaling activity defines skin tumor phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9349822" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12044012" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Gli and hedgehog in cancer: tumours, embryos and stem cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10504446" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Gli1 protein is expressed in basal cell carcinomas, outer root sheath keratinocytes and a subpopulation of mesenchymal cells in normal human skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8706127" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The Drosophila smoothened gene encodes a seven-pass membrane protein, a putative receptor for the hedgehog signal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9422511" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Activating Smoothened mutations in sporadic basal-cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15140221" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : FOXE1, a new transcriptional target of GLI2 is expressed in human epidermis and basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9892966" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Basal cell carcinoma development is associated with induction of the expression of the transcription factor Gli-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10630637" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The hedgehog signalling pathway in tumorigenesis and development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12015606" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29274272" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The role of the Hedgehog signaling pathway in cancer: A comprehensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9115210" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Basal cell carcinomas in mice overexpressing sonic hedgehog.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10233224" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Overexpression of the human homologue of Drosophila patched (PTCH) in skin tumours: specificity for basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11523056" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Expression of the Sonic Hedgehog receptor "PATCHED" in basal cell carcinomas and odontogenic keratocysts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15308259" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : PTC gene mutations and expression of SHH, PTC, SMO, and GLI-1 in odontogenic keratocysts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29753700" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21152126" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Basal cell carcinomas in gorlin syndrome: a review of 202 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26297395" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A systematic review of the literature of nevoid basal cell carcinoma syndrome affecting East Asians and North Europeans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9096761" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25159867" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Common variants modify the age of onset for basal cell carcinomas in Gorlin syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3547011" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Nevoid basal-cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27902821" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Risk Factors for Basal Cell Carcinoma Among Patients With Basal Cell Nevus Syndrome: Development of a Basal Cell Nevus Syndrome Patient Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6736355" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Nevoid basal cell carcinoma syndrome. Profile of genetic and environmental factors in oncogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28328109" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Cohort study of Gorlin syndrome with emphasis on standardised phenotyping and quality of life assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8315076" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Sun exposure and basal cell carcinomas in the nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29111235" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Genomic Stability in Syndromic Basal Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3668009" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The nevoid basal cell carcinoma syndrome: sensitivity to ultraviolet and x-ray irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9010431" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Multiple neoplasms following craniospinal irradiation for medulloblastoma in a patient with nevoid basal cell carcinoma syndrome. Case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7577601" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Multiple superficial basal cell carcinomas (basalomatosis) following cobalt irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11878577" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Prognostic factors and secondary malignancies in childhood medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9388465" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Abnormal DNA synthesis activity induced by X-rays in nevoid basal cell carcinoma syndrome cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14871823" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Basal cell carcinoma and its development: insights from radiation-induced tumors in Ptch1-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17850439" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14987156" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Molecular analysis to demonstrate that odontogenic keratocysts are neoplastic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28011178" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Recurrence probability for keratocystic odontogenic tumors: An analysis of 6427 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16430736" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Immunohistochemical analysis of the biological potential of odontogenic keratocysts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29564556" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Immunohistochemical evaluation of Sonic Hedgehog signaling pathway proteins (Shh, Ptch1, Ptch2, Smo, Gli1, Gli2, and Gli3) in sporadic and syndromic odontogenic keratocysts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6753760" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : "The basal-cell nevus" by Howell and Caro, January 1959. Commentary: The nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8042672" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Clinical findings in two African-American families with the nevoid basal cell carcinoma syndrome (NBCC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11250631" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Odontogenic keratocyst: Review of 256 cases for recurrence and clinicopathologic parameters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1065842" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The odontogenic keratocyst. A clinicopathologic study of 312 cases. Part I. Clinical features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8352281" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Further localization of the gene for nevoid basal cell carcinoma syndrome (NBCCS) in 15 Australasian families: linkage and loss of heterozygosity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7795971" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The diagnostic implication of falcine calcification on plain skull radiographs of patients with basal cell naevus syndrome and the incidence of falcine calcification in their relatives and two control groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/644054" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Nevoid basal cell carcinoma syndrome: radiographic manifestations including cystlike lesions of the phalanges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3537024" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Nevoid basal cell carcinoma syndrome. A review and case report of a patient with unilateral basal cell nevus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5501899" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Pursuit of the pits in the nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7053833" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Basal cell epithelioma (carcinoma) in children and teenagers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/509397" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The basal cell nevus syndrome: disasters occurring among a series of 36 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1931625" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2098052" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Medulloblastoma in the nevoid basal-cell carcinoma syndrome: case reports and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12879481" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22508808" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6707662" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Basal cell naevus syndrome and intracranial meningioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24517962" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Myogenic tumors in nevoid Basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18300799" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Cutaneous fetal rhabdomyoma: a case report and historical review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21917598" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Childhood rhabdomyosarcoma: recent advances and prospective views.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35333541" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease Severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7627481" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The prevalence of cervical and thoracic congenital skeletal abnormalities in basal cell naevus syndrome; a review of cervical and chest radiographs in 80 patients with BCNS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32964316" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Intracardiac tumor as a rare manifestation of genetic syndromes-presentation of a family with Gorlin syndrome and a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3010689" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : The Gorlin syndrome: a genetically determined disorder associated with cardiac tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14667615" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Surgical resection of ventricular cardiac fibromas: early and late results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7712637" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6703200" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Fibrosarcoma of ovary. A new component in the nevoid basal-cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4697853" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The basal cell naevus syndrome. Report of a family with anosmia and a case of hypogonadotrophic hypopituitarism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1409143" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Fetal rhabdomyoma and nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21623100" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Oral diffuse B-cell non-Hodgkin's lymphoma associated to Gorlin-Goltz syndrome: a case report with one year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17652545" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Undifferentiated sinonasal carcinoma in a patient with nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21834049" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34375441" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : A guideline for the clinical management of basal cell naevus syndrome (Gorlin-Goltz syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34611197" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Proposed criteria for nevoid basal cell carcinoma syndrome in children assessed using statistical optimization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14986757" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Odontogenic keratocysts in nevoid basal cell carcinoma (Gorlin's) syndrome: CT and MRI evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30653245" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Skin Cancer Associated Genodermatoses: A Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27617124" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Overgrowth Syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16780482" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : What syndrome is this? Bazex-Dupre-Christol syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6177160" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11422044" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : A case of Rombo syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26971504" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Brooke-Spiegler Syndrome and Phenotypic Variants: An Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23379543" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14725671" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Full-face carbon dioxide laser resurfacing in the management of a patient with the nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11896785" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Ultrapulse CO2 used for the successful treatment of basal cell carcinomas found in patients with basal cell nevus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9339279" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Gorlin's syndrome: the role of the carbon dioxide laser in patient management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9519602" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Microscopically controlled surgical excision combined with ultrapulse CO2 vaporization in the management of a patient with the nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8621834" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Different treatment modalities for the management of a patient with the nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12227875" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12459530" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14616807" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10848940" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15204165" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Topical application of imiquimod for the treatment of high-risk facial basal cell carcinoma in Gorlin syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16898919" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16485873" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Broad area photodynamic therapy for treatment of multiple basal cell carcinomas in a patient with nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15209801" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18813320" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Basal cell carcinomas: attack of the hedgehog.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31990414" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22670904" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27838224" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22910979" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23677114" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30003981" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25981810" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28846163" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21430703" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26488693" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15787821" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3287161" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1738183" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17928730" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Keratocystic odontogenic tumor: a 10-year retrospective study of 83 cases in an Iranian population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8028920" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Malignant potential of the odontogenic keratocyst.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15454770" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Malignant odontogenic tumors: a 22-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15113575" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Primary intraosseous carcinoma of the jaws arising from an odontogenic cyst--a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422324" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24623282" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9201152" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Complications of the nevoid basal cell carcinoma syndrome: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20956641" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : High prevalence of vitamin D deficiency in patients with basal cell nevus syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
